The Cognitive Benefits of Psychoactive Drug Therapy on PTSD

Post-Traumatic Stress Disorder (PTSD) is a debilitating psychiatric condition that remains highly resistant to conventional treatments such as selective serotonin reuptake inhibitors (SSRIs) and cognitive-behavioral therapy. Emerging research suggests that psychoactive drug therapies, including psilocybin, MDMA, and ketamine, may offer novel therapeutic pathways by promoting neuroplasticity, enhancing emotional processing, and increasing cognitive flexibility. The present study proposes a randomized controlled trial to evaluate the efficacy of these three psychoactive treatments compared to supportive therapy without drug intervention. Participants (N = 120) meeting DSM-5 criteria for PTSD will be randomly assigned to one of four conditions and assessed at baseline, 1 week, 1 month, and 3 months post-treatment. Primary outcome measures include PTSD symptom severity (CAPS-5), emotion regulation (DERS), and cognitive flexibility (CFI), with resting-state fMRI collected from a subsample. It is anticipated that psilocybin and MDMA will produce greater reductions in PTSD symptoms and greater improvements in emotion regulation and cognitive flexibility than ketamine or control. Findings are expected to advance neurobiological models of PTSD recovery and support the development of personalized, integrative treatments for trauma-related disorders.